Study S001738

Investigation on Safety, Tolerability and Pharmacokinetics of Liraglutide-depot in Healthy Subjects. A Randomised, Double-blind, Placebo-controlled Trial Investigating Subcutaneously Single Dose Escalation of a Sustained Release Formulation of Liraglutide Lysine in Healthy Male Subjects

ClinicalTrials.gov record

Registration

Registration: NCT01473953
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: DOUBLE
Status: COMPLETED
Enrollment: 31
Start: 2011-10
Primary completion: 2012-03
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes; Diabetes Mellitus, Type 2; Healthy
Interventions: DRUG:liraglutide-depot; DRUG:placebo
Results posted: TRUE
Secondary identifiers: OTHER:U1111-1123-0547

Registered primary outcomes

Number of Treatment Emergent Adverse Events (TEAEs) [Day 0 and up to 21 days after treatment]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.